Induced Pluripotent Stem Cell (iPSC) Market Competition Analysis 2026: How Players Are Shaping Growth
Induced Pluripotent Stem Cell (iPSC) Global Market Report 2025_Competitors
The Business Research Company's Induced Pluripotent Stem Cell (iPSC) Global Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035
LONDON, GREATER LONDON, UNITED KINGDOM, January 2, 2026 /EINPresswire.com/ -- The Induced Pluripotent Stem Cell (iPSC) market is dominated by a mix of global leading biotechnology companies, stem cell technology pioneers, and specialized research organizations. Companies are focusing on advanced reprogramming methods, scalable iPSC manufacturing platforms, and high-quality cell line development to strengthen market presence and support clinical-grade applications. Growing emphasis on precision disease modelling, personalized drug screening, and regenerative therapies is driving innovation across the sector. Understanding the competitive landscape is crucial for stakeholders aiming to identify collaboration opportunities, strategic partnerships.
Which Market Player Is Leading the Induced Pluripotent Stem Cell (iPSC) Market?
According to our research, FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) led global sales in 2023 with a 9% market share. The Healthcare division of the company is partially involved in the induced pluripotent stem cell (iPSC) market, provides the induced pluripotent stem cell (iPSC) technologies, providing GMP-grade iPSCs and iPSC-derived cells for applications in drug discovery, contract development and manufacturing services (CDMO), and cell therapies targeting unmet medical needs such as age-related macular degeneration, retinitis pigmentosa, and heart diseases.
How Concentrated Is the Induced Pluripotent Stem Cell (iPSC) Market?
The market is concentrated, with the top 10 players accounting for 31% of total market revenue in 2023. This level of concentration reflects the technical expertise, specialized infrastructure, and regulatory compliance required to operate in the iPSC space, which creates moderate entry barriers for new entrants. Leading vendors such as FUJIFILM Cellular Dynamics, Thermo Fisher Scientific, STEMCELL Technologies, Lonza Group, and Miltenyi Biotec maintain their positions through robust product portfolios, strong research collaborations, and established client trust, while numerous smaller firms address niche applications in drug discovery, regenerative medicine, and cell therapy. As adoption of iPSC technologies accelerates, strategic partnerships, acquisitions, and technology advancements are expected to further strengthen the influence of major players within the broader iPSC market.
• Leading companies include:
o FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) (9%)
o Thermo Fisher Scientific Inc. (7%)
o STEMCELL Technologies Inc. (4%)
o Lonza Group AG (3%)
o Miltenyi Biotec GmbH (3%)
o Takara Bio Inc. (2%)
o Astellas Pharma Inc. (1%)
o Fate Therapeutics Inc. (1%)
o ViaCyte Inc. (1%)
o Sartorius (1%)
Request a free sample of the Induced Pluripotent Stem Cell (iPSC) Market report
https://www.thebusinessresearchcompany.com/sample_request?id=2515&type=smp
Which Companies Are Leading Across Different Regions?
• North America: OmniaBio Inc., MEDIPOST Co., Ltd., STEMCELL Technologies Inc., QHP Capital, Applied StemCell, Inc., Century Therapeutics, Inc., Bristol Myers Squibb Company, StemCyte, Inc., Vertex Pharmaceuticals Incorporated, Thermo Fisher Scientific Inc., Fate Therapeutics, Inc., ThermoGenesis Holdings, Inc., BioCanRx, CellCAN, CCRM (Centre for Commercialization of Regenerative Medicine) and C3i Center Inc. are leading companies in this region.
• Asia Pacific: Cynata Therapeutics Limited, FUJIFILM Cellular Dynamics, Inc., Shenzhen Bioscience, Dainippon Sumitomo Pharma, Shanghai Cell Therapy Group, Car-T Bio, JW Therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takara Bio, Shinobi Therapeutics, Merck Sharp & Dohme, Evolus, Merz Pharma, AbbVie, Ipsen, AusBiotech Ltd, LifeCell International, iPS Bio, Inc., Karis Bio, Cellino Biotech, MEDIPOST Co., Ltd., Qilu Pharmaceutical Co., Ltd., Japan Tissue Engineering Co., Ltd., Nuwacell Biotechnologies Co., Ltd., Shanghai IxCell Biotech Co., Ltd., iRegene Therapeutics, CellSeed, Inc. and Celltrion are leading companies in this region.
• Western Europe: Merz Pharma GmbH & Co. KGaA, AbbVie Inc., Ipsen S.A., Evolus, Inc., Galderma S.A., HUGEL, Inc., Croma-Pharma GmbH, Fastox Pharma SA, Lonza Group Ltd, Avectas Ltd, Albumedix Ltd, Kite Pharma, Inc., Gilead Sciences, Inc., ReNeuron Group plc, Smart Cells, Genenta Science S.p.A., CellGenix GmbH, Cellcolabs AB, Axol Bioscience Ltd, Rigenerand S.r.l., SEED Biosciences SA, Selvita S.A., Mabion S.A., Roche Holding AG, Resolution Therapeutics Ltd, Ncardia B.V. and Evotec SE are leading companies in this region.
• Eastern Europe: Selvita S.A., Mabion S.A., Alzheon, Inc., Merz Pharma GmbH & Co. KGaA, Evolus, Inc., Zentiva Group a.s., Bochemie a.s., Tolion Health, Sinclair Pharma Ltd, Pfizer Inc., Roche Holding AG, Pharmasyntez Group, Pure Biologics S.A., Proteon Pharmaceuticals S.A., GlaxoSmithKline plc, Parexel International Corporation, Bayer AG and Synbio Technologies are leading companies in this region.
• South America: Gameto, BioCells Argentina, Banco de Cordon del Peru and CryoHoldco are leading companies in this region.
What Are the Major Competitive Trends in the Market?
• Ready-to-use iPSC cell lines are transforming immune-cloaked cell lines to evade immune rejection, facilitating their use in allogeneic therapies.
• Example: Cellistic Allo Chassis (February 2025) assigns ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ (hematopoietic stem cells) and CD4+ (helper T-cell) primary cells.
• These innovative cell lines are available for immediate use and customization, streamlining the development of cell therapies for various applications.
Which Strategies Are Companies Adopting to Stay Ahead?
•Launching advanced iPSC-based technologies to diversify the therapeutic portfolio
• Enhancing strategic collaborations and funding to accelerate R&D and manufacturing expansion
• Focusing on automation, digital bioprocessing, and AI-driven cell characterization for higher efficiency
• Leveraging advanced biomanufacturing platforms to scale iPSC production and reduce operational risk
Access the detailed Induced Pluripotent Stem Cell (iPSC) Market report here
https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
